Inozyme Pharma, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Depreciation expense
Write-off of acquired in-process research and development
Loss on disposal of fixed assets
Stock-based compensation expense
Amortization of premiums and discounts on marketable securities
Reduction in the carrying value of right-of-use assets
Non-cash interest expense and amortization of debt issuance costs
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable
Accrued expenses
Operating lease liabilities
Prepaid expenses, net of current portion
Other assets
Other long-term liabilities

Net cash used in operating activities
Investing activities
Purchases of marketable securities
Maturities of marketable securities
Purchases of property and equipment
Net cash provided by (used in) investing activities
Financing activities
Proceeds from issuance of Series A-2 Convertible Preferred Stock, net of issuance costs
Net proceeds from issuance of pre-funded warrants
Net proceeds from issuance of long-term debt
Proceeds from exercise of stock options
Proceeds from issuance of common stock for cash under employee stock purchase plan
Proceeds from initial public offering, net of offering costs
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Net decrease (increase) in cash, cash equivalents, and restricted cash
Effect of foreign currency exchange rate in cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Issuance of shares to acquire in-process research and development
Property and equipment unpaid at end of period
Right-of-use asset at adoption of Topic 842
Operating lease liabilities at adoption of Topic 842
Cash paid for interest
Deferred offering costs in accrued expenses
Deferred lease obligations - non-cash
Supplemental cash flow information:
Cash and cash equivalents
Restricted cash

Comments